Pan-TGFβ inhibition by SAR439459 relieves immunosuppression and improves antitumor efficacy of PD-1 blockade
Rita Greco, Hongjing Qu, Hui Qu, Joachim Theilhaber, Gary Shapiro, Richard C. Gregory, Christopher Winter, Natalia V. Malkova, Frank F. Sun, Julie Jaworski, Annie Best, Lily Pao, Andrew Hebert, Mikhail Levit, Alexei Protopopov, Jack Pollard, Keith S. Bahjat, Dmitri Wiederschain, Sharad Sharma
Abstract
T cell responses. Together, these data support the hypothesis that TGFβ neutralization using SAR439459 synergizes with PD-1 blockade to promote antitumor immunity and formed the basis for the ongoing clinical investigation of SAR439459 in patients with cancer (NCT03192345).
Topics & Concepts
BlockadeCancer researchCD8Transforming growth factorCytokineMedicineContext (archaeology)T cellImmune systemImmunosuppressionImmunologyImmunityProinflammatory cytokineCytotoxic T cellTumor microenvironmentPharmacologyBiologyIn vitroReceptorInflammationInternal medicineBiochemistryPaleontologyCancer Immunotherapy and BiomarkersImmune cells in cancerCancer Research and Treatments